New triple agonist drug produces substantial weight loss in diabetic patients
New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and appearing in The Lancet shows that treatment with the new triple agonist therapy retatrutide results in substantial weight loss and improvements in blood sugar control in people living with obesity or overweight and type 2 diabetes—a population that…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Pennsylvania records a fifth measles death as the nation endures its worst year since 1991
United Kingdom
-
Honeybee silk could power smarter wound dressings
United Kingdom
-
OnDosis and Adare Pharma Solutions announce strategic collaboration to advance OnDosis's lead U.S. ADHD program
United Kingdom
-
New antibiotic combinations aim to prevent recurrent bacterial vaginosis
United Kingdom
-
Study examines the real-world use of GLP-1 RA drugs in children and young people
United Kingdom
-
Menstrual tracking apps lack evidence of health and performance benefits
United Kingdom
-
Insurance hurdles and costs hinder access to blood cancer drugs
United Kingdom
-
Research reveals major impact of climate change on skin health worldwide
United Kingdom